PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY
L. H. Sehn,
I. Avivi,
J. Brody,
D. H. Yoon,
B. M. Elliott,
S. R. Siddani,
Y. Bai,
A. Parikh,
M. M. Seliem,
M. H. Dinh,
A. P. Skarbnik
Affiliations
L. H. Sehn
1 BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, Canada
I. Avivi
2 Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel
J. Brody
3 Icahn School of Medicine at Mount Sinai, New York, United States of America
D. H. Yoon
4 University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
B. M. Elliott
5 Genmab, Princeton
S. R. Siddani
6 AbbVie Inc., North Chicago
Y. Bai
6 AbbVie Inc., North Chicago
A. Parikh
6 AbbVie Inc., North Chicago
M. M. Seliem
6 AbbVie Inc., North Chicago
M. H. Dinh
6 AbbVie Inc., North Chicago
A. P. Skarbnik
7 Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, United States of America
